Global Peptides and Macrocycle Drug Discovery Services and Platforms Market Outlook, 2020-2030 by Product, Drug Discovery Steps, Therapeutic Area, Company Size and Geography

DUBLIN, May 21, 2020 /PRNewswire/ -- The "Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030" report has been added to's offering.

This report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service/technology providers engaged in this market.

Over the past few years, peptides (including oligopeptides, polypeptides and synthetic peptides) and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers; drug development efforts focused on such molecules have significantly increased. This can be attributed to the benefits offered by the aforementioned drug classes, which include high target specificity, low toxicity and favorable safety profiles.

In fact, more than 60 peptide-based therapies and macrocycle drug molecules have been approved till date, across the globe. In addition, more than 400 peptide based drugs are currently being evaluated in clinical trials, while over 500 molecules are still in the early stages of development.

It has been reported that the overall process of drug development, from discovery of a molecule to its commercial launch, takes around 10-15 years and involves capital investments worth USD 4-10 billion. However, only a small proportion of the molecules, which are selected for further investigation during the initial stages of research, actually enter the market.

Given the complexities associated with the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical/biotechnology sector has steadily increased over time. Specifically, the discovery of peptides and macrocycles for therapeutic use is a long, arduous and cost intensive process.

As a result, many developers are opting to outsource such operations to contract research organizations (CROs) that claim to specialize in this regard. In addition, there are multiple technology platform providers, which offer licenses to proprietary peptide discovery platforms that can be used by interested drug developers/manufacturers.

We believe that, as the demand for peptide-based therapeutics increases, the opportunity for contract service provides and technology developers engaged in this domain is also likely to grow in the foreseen future.

Report Objectives

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the peptides and macrocycle drug discovery services market. Based on multiple parameters, such as R&D spend, we have developed an informed estimate on the financial evolution of the market over the period, 2020-2030.

The report also provides details on the likely distribution of the current and forecasted opportunity across:

    --  [A] different type of product (synthetic peptides, biological and
        recombinant peptides and macrocycles)
    --  [B] drug discovery steps (target identification and validation, hit
        identification, lead generation and lead optimization)
    --  [C] therapeutic area (oncological disorders, metabolic disorders,
        cardiovascular disorders, infectious disorders, urological disorders,
        endocrine disorders, CNS disorders, and other diseases)
    --  [D] company size (small, mid-sized and large and very large companies)
    --  [E] geography (North America, Europe, Asia-Pacific)

Amongst other elements, the report includes:

    --  A detailed assessment of the current market landscape of companies
        offering peptide and macrocycle drug discovery services, including
        developer information (year of establishment, company size and location
        of headquarters), type of peptide manufactured (linear, cyclic, helical
        and others), drug discovery steps covered in service portfolio (target
        validation, hit identification, lead generation and lead optimization),
        peptide generation methods used (liquid phase synthesis, solid phase
        synthesis, microwave-assisted synthesis, recombinant methods and
        others), peptide modification services (C-terminal, N-terminal,
        fret/quenching tags, immunogenic conjugates, linkers/spacers, unnatural
        AAS, cyclization, stable isotope labels and post-translational
        modification services) and other services offered (peptide
        isolation/purification service, peptide detection/identification service
        and peptide quantification service).
    --  An insightful geographical benchmarking of the capabilities of companies
        of various sizes, highlighting the key focus areas, comparing their
        existing strengths both within and beyond their respective peer groups
        (based on geography and company size).
    --  An in-depth analysis of peptide platform and library service providers,
        featuring information on their company details (year of establishment,
        company size and location of headquarters), purpose of the platform,
        type of peptide manufactured (linear, cyclic, helical and others) and
        platform access model (pipeline licensing, technology licensing,
        strategic alliance and library provider).
    --  Profiles of peptides and macrocycle drug discovery service providers,
        featuring information on the year of establishment, location of
        headquarters, peptide discovery service/platform portfolio, recent
        developments and an informed future outlook.
    --  An analysis of the partnerships that have been established in the recent
        past, covering R&D agreements, licensing agreements, acquisitions and
        other form of collaborations.

To account for the uncertainties associated with the drug discovery services and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines


3.1. Chapter Overview
3.2. History of Peptide Drugs
3.3. Structure of Peptides
3.4. Major Classes of Peptides
3.4.1. Dipeptides
3.4.2. Depsipeptides
3.4.3. Cyclic Peptides / Macrocycles
3.4.4. Other Types of Peptides
3.5. Steps Involved in the Discovery of Peptides
3.6. Synthesis of Peptides
3.7. Modification of Peptides
3.8. Tools and Techniques for Peptide Analysis
3.9. Delivery of Peptides
3.10. Applications of Peptides
3.11. Role of Contract Research Organizations (CROs) in Drug Discovery
3.12. Risks Associated with Outsourcing Research Operations
3.13. Key Considerations for Selecting a Suitable CRO Partner

4.1. Chapter Overview
4.2. Peptides and Macrocycle Drug Discovery Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Peptide
4.2.5. Analysis by Drug Discovery Steps
4.2.6. Analysis by Peptide Generation Method Used
4.2.7. Analysis by Peptide Modification Method Used
4.2.8. Analysis by Other Services Offered

5.1. Chapter Overview
5.2. Methodology
5.3. Benchmarking by Region
5.3.1. Europe, Peer Group I
5.3.2. North America, Peer Group II
5.3.3. Asia Pacific, Peer Group III
5.4. Benchmarking by Company Size
5.4.1. Small Companies, Peer Group I
5.4.2. Mid-Sized Companies, Peer Group II
5.4.3. Large and Very Large Companies, Peer Group III
5.5. Concluding Remarks

6.1. Chapter Overview
6.2. Peptides and Macrocycle Drug Discovery Platform Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Peptide
6.2.5. Analysis by Platform Access Model

7.1. Chapter Overview
7.2. Peptides and Macrocycle Drug Discovery Service Providers
7.2.1. GenScript Company Overview Service Portfolio Future Outlook
7.2.2. JPT Peptide Technologies
7.2.3. CPC Scientific
7.2.4. IRBM
7.2.5. Creative Peptides
7.2.6. Pepscan
7.3 Peptides and Macrocycle Drug Discovery Platform Providers
7.3.1. Interprotein
7.3.2. RA Pharmaceuticals
7.3.3. Pepticom
7.3.4. PeptiDream
7.3.5. Creative Biolabs
7.3.6. MeSCue-Janusys

8.1. Chapter Overview
8.2. Partnership Models
8.3. Peptides and Macrocycle Drug Discovery Service and Platform Providers: List of Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Peptide
8.3.5. Analysis by Focus Area
8.3.6. Most Active Players: Analysis by Number and Type of Partnership
8.3.7. Geographical Analysis Continent-wise Distribution Country-wise Distribution

9.1. Chapter Overview
9.2. Key Assumptions and Forecast Methodology
9.3. Overall Peptide Drug Discovery Services Market, 2020-2030
9.4. Peptide Drug Discovery Services Market: Analysis by Type of Peptide, 2020, 2025 and 2030
9.4.1. Peptide Drug Discovery Services Market for Synthetic Peptides, 2020-2030
9.4.2. Peptide Drug Discovery Services Market for Biologic and Recombinant Peptides, 2020-2030
9.4.3. Peptide Drug Discovery Services Market for Macrocycles, 2020-2030
9.5. Peptide Drug Discovery Services Market: Analysis by Drug Discovery Steps, 2020, 2025 and 2030
9.6. Peptide Drug Discovery Services Market: Analysis by Therapeutic Area, 2020-2030
9.7. Peptide Drug Discovery Services Market: Analysis by Company Size, 2020-2030
9.8. Peptide Drug Discovery Services Market: Analysis by Geography, 2020, 2025 and 2030

10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
10.6. Concluding Remarks

11.1. Chapter Overview
11.2. Key Takeaways

12.1. Chapter Overview
12.2. Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
12.3. Anonymous

Companies Mentioned

    --  3B Pharmaceuticals
    --  AI Squared
    --  AiCuris
    --  Aileron Therapeutics
    --  Alexion
    --  Ampersand Capital Partners
    --  Apigenix
    --  Apitope
    --  Asahi Kasei Pharma
    --  Astellas Pharma
    --  AstraZeneca
    --  Aurigene Discovery Technologies
    --  Bayer
    --  Bicycle Therapeutics
    --  BIND Therapeutics
    --  Bio-Synthesis
    --  Blue Ridge Biosciences
    --  Boehringer Ingelheim
    --  Bristol-Myers Squibb
    --  Bruker
    --  Cambridge Research Biochemicals
    --  ChemBridge
    --  ChemPartner
    --  Circle Pharma
    --  CMDBioscience
    --  CPC Scientific
    --  Creative Biolabs
    --  Creative Peptides
    --  Cyclenium Pharma
    --  Cyclogenix
    --  Dementia Discovery Fund
    --  Domainex
    --  Eli Lilly
    --  Encycle Therapeutics
    --  Eurofins
    --  Fraunhofer Institute
    --  EMC Microcollection
    --  Fujitsu
    --  Fundacin MEDINA
    --  Genentech
    --  GenScript
    --  Gilead
    --  Grey Matter
    --  Gubra
    --  GVK BIO
    --  Hanmi
    --  Haplogen
    --  Heptares Therapeutics
    --  Interprotein Corporation
    --  Ipsen
    --  IRBM
    --  Isogenica
    --  Janssen Pharmaceuticals
    --  JCR Pharmaceuticals
    --  Jitsubo
    --  JPT Peptide Technologies
    --  Kallyope
    --  Kawasaki Medical School
    --  Kleo Pharmaceuticals
    --  KYORIN Pharmaceutical
    --  Lanthio Pharma
    --  Maastricht University
    --  Macrocyclics
    --  McGill University
    --  Menten
    --  MercachemSyncom
    --  Merck
    --  MeSCue-Janusys
    --  Mimotopes
    --  Morphosys
    --  Navigen Pharmaceuticals
    --  Neuland Laboratories
    --  New England BioGroup
    --  Nihon Medi-Physics
    --  Nimble Therapeutics
    --  Novartis
    --  Novo Nordisk
    --  NUMAFERM
    --  Nuritas
    --  Oncodesign
    --  Ono Pharmaceutical
    --  Orbit Discovery
    --  Oxford University
    --  Pepscan
    --  Pepticom
    --  Peptides International
    --  PeptiDream
    --  Pfizer
    --  Phylogica Limited
    --  Polyphor
    --  Prestwick Chemical
    --  Priveel Peptides
    --  ProteoGenix
    --  Provepharm Life Solutions
    --  Ra Pharma
    --  Red Glead Discovery
    --  RS Synthesis
    --  Sanofi
    --  Santen Pharmaceutical
    --  Sapience Therapeutics
    --  Senn Chemicals
    --  Shionogi
    --  Smartox Biotechnology
    --  Sosei Group
    --  Taisho Pharmaceutical
    --  Taros
    --  TCG Lifesciences
    --  Teijin Pharma
    --  Thermo Fisher Scientific
    --  Oxurion (previously known as ThromboGenics)
    --  Tokyo Institute of Technology
    --  UCB
    --  UniQuest
    --  University of Bath
    --  Zealand Pharma

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets